By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
November Lease Deals for the 2025 Kia EV6 are Too Good to Pass Up - 2Little Urban areas to Visit in Western Europe
- 3In Antarctica, photos show a remote area teeming with life amid growing risks from climate change
- 4Bayer reports positive results for blood thinner after 2023 setback
- 5The Best Computer games Ever
- Sean Penn lights up, Kylie Jenner gets A-list approval and 7 other moments you didn’t see at the Golden Globes
- 5 Language Learning Applications
- Avoid This Common Mistake When Planning Sightseeing Activities For Your Trip To Italy
- Grammy nominations 2026: Full list of nominees in every major category, including Album of the Year and Best New Artist
- Limited Rain Chances in Brazil Boost Coffee Prices
- Hot peppers sent him to the ER. Two years later, a ‘ghost bill’ arrived.
- Don't fall for it: These common tourist scams in Rome are easy to avoid if you know what you're looking for
- NASA's moon mission has begun — here's what's ahead for the Artemis II astronauts
- How to watch ‘The Traitors’ U.K. Season 4 from the U.S.
